Kaplan-Meier estimates of virological failure >50 copies/mL.

<p>Kaplan-Meier estimates of virological failure >50 copies/mL.</p

Kaplan-Meier estimates of time to HIV-RNA >200 copies/mL or stop or intensification of PI/r monotherapy according to main predictors strata.

<p>TND = target not detected.</p

Kaplan-Meier estimates of virological failure >200 copies/mL.

<p>Kaplan-Meier estimates of virological failure >200 copies/mL.</p

Kaplan-Meier estimates of time to HIV-RNA >200 copies/mL or stop or intensification of PI/r monotherapy.

<p>Kaplan-Meier estimates of time to HIV-RNA >200 copies/mL or stop or intensification of PI/r monotherapy.</p

Relative hazards of composite outcome from fitting a Cox regression analysis—PI/r-monotherapy score with all 8 pre-selected variables.

<p>Relative hazards of composite outcome from fitting a Cox regression analysis—PI/r-monotherapy score with all 8 pre-selected variables.</p

Characteristics of patients starting PI/r-based monotherapy.

<p>Characteristics of patients starting PI/r-based monotherapy.</p

Cox regression prediction estimates of treatment failure for exact values of CD4 count nadir.

<p>Cox regression prediction estimates of treatment failure for exact values of CD4 count nadir.</p

Drug resistance mutations (DRMs) in patients who showed virological failure to boosted-protease inhibitors monotherapy and with genotypic resistance testing available at failure.

<p>Drug resistance mutations (DRMs) in patients who showed virological failure to boosted-protease inhibitors monotherapy and with genotypic resistance testing available at failure.</p

Adverse events.

<p>Adverse events.</p

Patient’s characteristics (n = 280.

<p>Patient’s characteristics (n = 280.</p